PKD2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL31598769	1.00	1/20
SCHEMBL31598806	0.88	1/20
SCHEMBL31598766	0.82	1/20
SCHEMBL31598789	0.81	1/20
SCHEMBL31598777	0.81	1/20
SCHEMBL31598767	0.78	1/20
SCHEMBL31598801	0.76	1/20
SCHEMBL31598819	0.74	1/20
SCHEMBL31598783	0.73	1/20
SCHEMBL31598711	0.72	1/20
SCHEMBL31598726	0.70	1/20
SCHEMBL31598754	0.70	1/20
SCHEMBL31598791	0.69	1/20
SCHEMBL31598755	0.69	1/20
SCHEMBL31598811	0.60	1/20
SCHEMBL31598805	0.52	1/20
SCHEMBL31598840	0.44	1/20
SCHEMBL31598779	0.43	1/20
SCHEMBL31598796	0.42	1/20
SCHEMBL31598830	0.41	1/20

Clinical trials — most relevant to PKD2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease	PHASE4	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease	PHASE2	COMPLETED
Bempedoic Acid Therapy for Polycystic Kidney Disease	PHASE2	NOT_YET_RECRUITING
Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)	PHASE2	COMPLETED
Effect of the Aquaretic Tolvaptan on Nitric Oxide System	PHASE2	COMPLETED
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	PHASE2	COMPLETED
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease	PHASE1	RECRUITING
Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository	nan	ENROLLING_BY_INVITATION
The Vienna RAP Pilot Study	nan	COMPLETED
A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province	nan	COMPLETED
Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease	nan	ACTIVE_NOT_RECRUITING
Evaluation of Nephrectomy Specimen for Intracranial Aneurysm Development in ADPKD	nan	COMPLETED
Evaluation of Iliac and Renal Artery for Mechanism of Intracranial Aneurysm in ADPKD	nan	UNKNOWN
Outcome of ADPKD With Octreotide LAR	nan	ACTIVE_NOT_RECRUITING
Imaging Assessments of ARPKD Kidney Disease Progression	nan	RECRUITING
Pyruvate Kinase Deficiency Natural History Study	nan	COMPLETED
Role of ROS and cAMP-PKA Biomarkers in ADPKD	nan	ACTIVE_NOT_RECRUITING
High Water Intake in Polycystic Kidney Disease	nan	COMPLETED
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease	nan	ACTIVE_NOT_RECRUITING
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease	nan	COMPLETED
Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD	nan	COMPLETED
Early PKD Observational Cohort Study	nan	RECRUITING
Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	nan	COMPLETED
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping	nan	COMPLETED
Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease	nan	NOT_YET_RECRUITING
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease	nan	COMPLETED
Efficacy of Tolvaptan on ADPKD Patients	nan	UNKNOWN
Repository Study of Autosomal Dominant Polycystic Kidney Disease	nan	WITHDRAWN
A Prospective Observational Study of Foam Sclerotherapy .	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PKD2 binder may also engage these)

Protein	Name	Similarity
Q4GZT3	—	1.000	Q4GZT3 →
O35245	—	0.995	O35245 →
Q9P0L9	—	0.970	Q9P0L9 →
O62826	—	0.970	O62826 →
Q9R283	—	0.969	Q9R283 →
Q6IVV8	—	0.968	Q6IVV8 →
MCOLN1	Mucolipin-1	0.964	landscape →
Q9R244	—	0.964	Q9R244 →
A2A259	—	0.963	A2A259 →
Q99J21	—	0.962	Q99J21 →
Q60HE8	—	0.961	Q60HE8 →
A6QM06	—	0.961	A6QM06 →
P97260	—	0.960	P97260 →
P56726	—	0.960	P56726 →
P97698	—	0.959	P97698 →
Q5MNU5	—	0.959	Q5MNU5 →
A2RRU4	—	0.959	A2RRU4 →
Q5GH73	—	0.959	Q5GH73 →
Q12770	—	0.959	Q12770 →
Q6GQT6	—	0.958	Q6GQT6 →
SMO	Protein smoothened	0.958	landscape →
F1N2W9	—	0.958	F1N2W9 →
Q61143	—	0.957	Q61143 →
E1BBQ2	—	0.957	E1BBQ2 →
Q5GH57	—	0.956	Q5GH57 →
E9Q6C8	—	0.956	E9Q6C8 →
D4A6L0	—	0.955	D4A6L0 →
TRPC6	Short transient receptor potential channel 6	0.954	landscape →
KCNK13	Potassium channel subfamily K member 13	0.954	landscape →
Q9NRU3	—	0.954	Q9NRU3 →